Brought to you by 
Novartis gets rights to Arrow Therapeutics' A60444 for RSV
03 Dec 2015
Executive Summary
Novartis will work with Arrow Therapeutics (drugs for infectious diseases) on the development of the Phase IIa small-molecule inhibitor, A60444, to treat respiratory syncytial virus (RSV).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis gets rights to Arrow Therapeutics' A60444 for RSV
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice